Acute Chest Pain Pathways: Reducing Missed MI Risk in India

Acute Chest Pain Pathways: How Structured Emergency Protocols Are Reducing Missed Heart Attacks and Unnecessary Hospital Stays in India

Chest pain remains one of the most frequent and anxiety inducing reasons for a visit to the emergency department, and it places emergency physicians in a genuinely difficult position. On one hand, missing an acute myocardial infarction can cost a life. On the other hand, admitting every patient with chest discomfort out of caution places enormous strain on hospital beds, cardiology teams, and healthcare budgets. This tension is exactly why acute chest pain pathways have become one of the most important developments in emergency and cardiac care worldwide, and increasingly, in India.

An acute chest pain pathway is a structured, evidence based protocol that guides clinicians through history taking, electrocardiography, and biomarker testing so that patients can be sorted quickly and safely into low, intermediate, or high risk categories. When implemented well, these pathways reduce missed diagnoses of acute coronary syndrome, cut down unnecessary hospital admissions, shorten the time patients spend in the emergency department, and lower the overall cost of care. For a country like India, where emergency departments are frequently overcrowded and cardiovascular disease strikes at a younger age than in Western populations, the case for adopting structured chest pain pathways is particularly strong.

This article examines why chest pain pathways matter, how they work clinically, what the Indian healthcare context demands, and how hospitals, doctors, and healthcare associations can work toward safer and more efficient chest pain management.

Understanding Acute Chest Pain Pathways

At its core, an acute chest pain pathway is a decision making framework, not a single test. It typically combines three pillars of assessment: a focused clinical history that considers the character, radiation, and triggers of the pain, a timely electrocardiogram interpreted by an experienced clinician, and serial biomarker testing using cardiac troponin. Australian and international guidelines emphasise that the priority is not necessarily to reach a definitive diagnosis immediately, but to accurately classify the patient's relative risk of a serious cardiac event within the first hours of presentation.

Globally, only a minority of patients presenting with acute chest pain are ultimately diagnosed with acute coronary syndrome. Data referenced in contemporary cardiology literature suggests that less than five percent of chest pain presentations turn out to be ST elevation myocardial infarction, another five to ten percent are non-ST elevation myocardial infarction, and a further five to ten percent are unstable angina. The remaining majority, often 50 to 60 percent, are eventually found to have a non-cardiac cause, ranging from musculoskeletal pain and gastro-oesophageal reflux to anxiety-related chest discomfort. This distribution is precisely why indiscriminate admission of every chest pain patient is neither efficient nor necessary, provided a reliable pathway exists to identify the smaller group who are genuinely at risk.

A well-designed pathway usually involves an initial ECG within ten minutes of arrival, a targeted history looking for cardiac versus non-cardiac features, and troponin testing using assay-specific protocols, most commonly a 0 and 1 hour or a 0 and 2 hour strategy when high sensitivity assays are available. Patients are then placed into a low-risk group suitable for early discharge with outpatient follow-up, an intermediate-risk group requiring further non-invasive testing, or a high-risk group requiring inpatient cardiology care and possible urgent intervention.

Why This Matters for the Indian Healthcare System

India's cardiovascular disease burden carries distinct characteristics that make structured chest pain assessment especially relevant. Coronary artery disease tends to affect Asian Indians five to ten years earlier than populations in Western countries, meaning emergency departments frequently see chest pain presentations in relatively younger patients, some without classic risk factors. Global Burden of Disease data has placed India's cardiovascular mortality rate above the global average, and the prevalence of coronary artery disease varies meaningfully between rural and urban populations, reflecting differences in lifestyle, dietary patterns, tobacco use, and access to timely care.

At the same time, India's emergency care infrastructure is uneven. Tertiary hospitals in metro cities and Tier 1 centres often have access to high-sensitivity troponin assays, dedicated cardiology units, and catheterisation laboratories. Many Tier 2 and Tier 3 hospitals, along with Primary Health Centres, continue to rely on conventional troponin assays that require longer testing intervals of six to twelve hours, or in some cases lack round-the-clock ECG interpretation altogether. The National Essential Diagnostic List mandates ECG availability even at the primary health centre level, yet compliance and quality of interpretation remain inconsistent across states.

Financial protection schemes such as Ayushman Bharat Pradhan Mantri Jan Arogya Yojana have expanded access to cardiac procedures for economically weaker sections, and studies from tertiary teaching hospitals have shown that beneficiaries under this scheme can receive selected cardiac surgeries with zero out-of-pocket expenditure. However, reimbursement delays and inconsistent empanelment of private hospitals continue to limit the scheme's full potential, particularly for time-sensitive emergency presentations where every hour matters.

Against this backdrop, the 2017 joint working group recommendations from the Indian College of Cardiology, the Academic College of Emergency Experts, and INDUSEM represented an important first step toward standardising low-risk chest pain management across Indian emergency departments. These recommendations recognised that accelerated diagnostic protocols could reduce hospitalisation rates by around 40 percent while keeping the 30 day risk of major adverse cardiac events below one percent, a safety margin considered acceptable by the vast majority of practising clinicians.

Recognising the Symptoms and Risk Factors

Chest pain due to myocardial ischaemia is classically described as a pressure, tightness, or heaviness behind the breastbone that may radiate to the jaw, neck, shoulders, or arms, and which tends to worsen with exertion and ease with rest. However, presentations vary considerably by sex, age, and individual physiology, and clinicians need to remain alert to atypical patterns.

Women are just as likely as men to experience chest pain during a cardiac event, but they more frequently report accompanying symptoms such as nausea, fatigue, breathlessness, and back or jaw discomfort, which can sometimes lead to underestimation of cardiac risk if these associated symptoms are not weighed carefully. Older adults, particularly those above seventy five years of age, may present with breathlessness, dizziness, or general unwellness rather than pain, sometimes referred to as anginal equivalents. Patients with diabetes may also have blunted pain perception due to autonomic neuropathy, meaning a heart attack can occur with minimal or no chest discomfort at all.

Recognised risk factors for coronary artery disease include older age, diabetes mellitus, hypertension, high cholesterol, obesity, tobacco use, and a family history of premature cardiovascular disease. In the Indian context, additional considerations include a genetic predisposition toward earlier onset coronary disease, high rates of central obesity and insulin resistance even at lower body mass index thresholds, and dietary patterns rich in refined carbohydrates and saturated fats that are increasingly common in urban Tier 1 and Tier 2 cities. Tobacco use, both smoked and smokeless, remains a significant and modifiable contributor, particularly in certain states and among younger populations.

It is worth noting that the absence of typical risk factors does not rule out acute coronary syndrome, since coronary events can also result from oxygen supply and demand mismatch, spontaneous coronary artery dissection, or coronary vasospasm, conditions that may occur in patients without conventional atherosclerotic risk profiles, including younger women and postpartum patients.

Diagnosis and Medical Evaluation Within the Pathway

The diagnostic backbone of any acute chest pain pathway rests on three elements working together rather than in isolation. The electrocardiogram remains the fastest and most critical tool, since it can immediately identify patients with ST elevation who require urgent reperfusion therapy. Guidelines recommend the first ECG be obtained and reviewed within ten minutes of a patient's arrival, with repeat tracings performed if symptoms persist, recur, or change in character.

High sensitivity cardiac troponin testing has transformed chest pain evaluation over the past decade. Compared with older, conventional troponin assays that required testing at six to twelve hour intervals, high sensitivity assays can detect much smaller elevations in circulating troponin and allow for validated 0 and 1 hour or 0 and 2 hour rule out protocols. A single high sensitivity troponin measurement, when the patient's symptom onset was more than two hours earlier, and the ECG shows no ischaemic changes, can safely classify a substantial proportion of patients as low risk. This single step alone has been one of the biggest contributors to reducing unnecessary hospital admissions internationally.

Clinical risk scores such as the HEART score, which considers History, ECG findings, Age, Risk factors, and initial Troponin, and the EDACS score continue to play a supporting role, particularly in centres that do not yet have access to high sensitivity assays. Indian studies evaluating the HEART score in emergency department settings have found it useful for identifying patients who can be safely discharged, though researchers have also cautioned that its performance can vary across different populations and clinical settings, and that age-related scoring may occasionally underestimate risk in younger patients or overestimate it in the elderly.

Where facilities allow, further evaluation for intermediate risk patients may include non-invasive imaging, most commonly computed tomography coronary angiography, or functional testing such as stress echocardiography. These tools help identify obstructive or non-obstructive coronary artery disease without the need for a full hospital admission, and a normal computed tomography coronary angiography carries a strong negative predictive value for several years.

Treatment Options and Management Strategies

Once a patient is risk stratified, management pathways diverge accordingly. High-risk patients, particularly those with ST elevation or high-risk features on ECG, require urgent transfer for reperfusion therapy, whether through primary angioplasty or thrombolysis, depending on facility availability and transfer times. India's tiered healthcare structure means that many high-risk patients first present at primary health centres or smaller hospitals lacking catheterisation laboratories, making rapid transfer protocols and telemedicine-supported ECG interpretation critically important, particularly in rural and semi-urban regions.

Intermediate risk patients benefit from a period of observation, serial troponin testing, and consideration of non-invasive testing, ideally within a dedicated short stay or chest pain observation unit rather than a general medical ward. International experience, particularly from countries with established chest pain unit networks, has shown that dedicated units reduce admission rates, shorten length of stay, and improve patient satisfaction without compromising safety.

Low-risk patients, who represent the largest proportion of chest pain presentations, are strong candidates for early and safe discharge once serious causes have been excluded. Clear, structured discharge communication becomes essential at this stage. Patients should be informed in plain language that a heart attack has been reasonably excluded, given guidance on when to seek re-evaluation, and where appropriate, referred to a general practitioner or cardiologist for outpatient risk factor assessment and management. Shared decision making, where patients are actively involved in understanding their risk and the rationale for discharge rather than admission, has been shown internationally to reduce unnecessary testing and improve patient confidence in the discharge decision.

Rapid access chest pain clinics represent a particularly promising model for the Indian context, especially in Tier 1 and larger Tier 2 cities. These clinics allow intermediate risk patients discharged from the emergency department to receive prompt outpatient cardiac evaluation within days rather than weeks, reducing both unnecessary admissions and the risk of patients being lost to follow-up.

Building Safer, More Efficient Chest Pain Pathways Across India

The evidence is fairly consistent across international settings, from the United Kingdom's National Health Service trusts to Australian cardiac networks, that structured chest pain pathways reduce hospital admissions, shorten time to treatment for those who need it, and improve overall patient experience, all while maintaining safety margins that keep missed diagnosis rates below one percent. Adapting these lessons for India requires attention to a few local realities.

First, standardisation of troponin assay use and reporting turnaround times across hospital tiers would help more facilities adopt accelerated protocols rather than relying on prolonged conventional testing. Second, strengthening ECG interpretation capacity at the primary and secondary care level, potentially supported by telemedicine links to cardiology specialists in tertiary centres, could reduce diagnostic delays in regions with limited on-site expertise. Third, embedding structured discharge communication and outpatient follow-up systems, potentially linked with government schemes such as Ayushman Bharat, would help ensure that low-risk patients who are safely discharged do not fall through the cracks of a fragmented follow-up system.

Finally, the medical community itself has an important role to play in driving this change. Sharing clinical experience, discussing implementation challenges, and highlighting successful chest pain pathway models within professional networks can accelerate adoption across institutions that might otherwise take years to update their protocols independently. Platforms built specifically for doctors and medical associations to exchange this kind of clinical and operational knowledge can meaningfully support this process, helping individual hospitals learn from each other rather than working in isolation.

Conclusion

Acute chest pain remains a diagnostic challenge precisely because the consequences of both underdiagnosis and overdiagnosis are significant. Missing a myocardial infarction can be fatal, while unnecessary admission burdens patients, families, and already stretched healthcare systems. Structured, evidence-based chest pain pathways, built around timely ECG assessment, high-sensitivity troponin protocols, and clear risk stratification, offer a proven way to strike this balance. For India, where cardiovascular disease strikes earlier and healthcare infrastructure varies widely between urban and rural settings, thoughtful adaptation and wider adoption of these pathways represents one of the most impactful steps the emergency and cardiology community can take toward safer, more efficient, and more equitable cardiac care.

Frequently Asked Questions

Q1: What is an acute chest pain pathway?

An acute chest pain pathway is a standardised, protocol-driven approach used in emergency departments to assess patients with chest pain. It combines clinical history, electrocardiography, and high sensitivity troponin testing to classify patients into low, intermediate, or high risk categories, guiding decisions on discharge, observation, or admission.

Q2: How accurate is high sensitivity troponin testing in ruling out a heart attack?

High sensitivity troponin assays, when used within a validated 0 or 1-hour or 0 or 2-hour protocol, can safely classify a large proportion of patients as low risk, with a 30-day risk of major adverse cardiac events below 1 percent. Accuracy depends on correct sample timing and assay-specific thresholds.

Q3: Why do many Indian hospitals still admit low-risk chest pain patients unnecessarily?

Many Indian hospitals continue to rely on conventional troponin assays with longer testing intervals, lack standardised chest pain protocols, and face medico-legal caution, all of which contribute to higher-than-necessary admission rates for low-risk patients.

Q4: Can women and older adults present with chest pain differently?

Yes. Women more often report associated symptoms such as nausea, fatigue, and breathlessness alongside or instead of classic chest pain, while older adults may present with angina equivalents like breathlessness or dizziness without significant chest discomfort, which can delay diagnosis if clinicians are not vigilant.

Q5: What role can rapid access chest pain clinics play in India?

Rapid access chest pain clinics allow intermediate-risk patients to undergo further cardiac evaluation as outpatients rather than through prolonged hospital admission. International data shows these clinics are safe, cost-effective, and improve patient satisfaction, and they represent a promising model for select urban Indian centres.

#ChestPainCare #HeartAttackAwareness